Lau Susanna K P, He Zirong, Tsang Chi-Ching, Chan Tony T Y, Luk Hayes K H, Chan Elaine, Li Kenneth S M, Fung Joshua, Chow Franklin W N, Tam Anthony R, Chung Tom W H, Wong Sally C Y, Que Tak-Lun, Fung Kitty S C, Lung David C, Wu Alan K L, Hung Ivan F N, Teng Jade L L, Wernery Ulrich, Hui Suk-Wai, Martelli Paolo, Woo Patrick C Y
Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong.
Microorganisms. 2021 May 10;9(5):1019. doi: 10.3390/microorganisms9051019.
In addition to human cases, cases of COVID-19 in captive animals and pets are increasingly reported. This raises the concern for two-way COVID-19 transmission between humans and animals. Here, we developed a SARS-CoV-2 nucleocapsid protein-based competitive enzyme-linked immunosorbent assay (cELISA) for serodiagnosis of COVID-19 which can theoretically be used in virtually all kinds of animals. We used 187 serum samples from patients with/without COVID-19, laboratory animals immunized with inactive SARS-CoV-2 virions, COVID-19-negative animals, and animals seropositive to other betacoronaviruses. A cut-off percent inhibition value of 22.345% was determined and the analytical sensitivity and specificity were found to be 1:64-1:256 and 93.9%, respectively. Evaluation on its diagnostic performance using 155 serum samples from COVID-19-negative animals and COVID-19 human patients showed a diagnostic sensitivity and specificity of 80.8% and 100%, respectively. The cELISA can be incorporated into routine blood testing of farmed/captive animals for COVID-19 surveillance.
除人类病例外，圈养动物和宠物感染新冠病毒的病例报告也日益增多。这引发了对新冠病毒在人和动物之间双向传播的担忧。在此，我们开发了一种基于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）核衣壳蛋白的竞争酶联免疫吸附测定法（cELISA）用于新冠病毒的血清学诊断，理论上可用于几乎所有种类的动物。我们使用了187份来自感染/未感染新冠病毒患者的血清样本、用灭活的SARS-CoV-2病毒粒子免疫的实验动物、新冠病毒阴性动物以及对其他β冠状病毒血清学阳性的动物。确定了22.345%的抑制率截断值，分析灵敏度和特异性分别为1:64至1:256和93.9%。使用来自新冠病毒阴性动物和新冠病毒患者的155份血清样本对其诊断性能进行评估，结果显示诊断灵敏度和特异性分别为80.8%和100%。该cELISA可纳入养殖/圈养动物的常规血液检测中，用于新冠病毒监测。
